Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	left ventricular cardiac muscle tissue morphogenesis	NAGLU RYR2 SMAD4	4.66e-07	7	50	3	GO:0003220
GeneOntologyBiologicalProcess	cardiac left ventricle morphogenesis	NAGLU RYR2 SMAD4	2.97e-05	25	50	3	GO:0003214
Domain	Cul7	CUL9 HERC2	2.10e-05	3	50	2	PF11515
Domain	CPH_domain	CUL9 HERC2	2.10e-05	3	50	2	IPR021097
Domain	PEROXIDASE_1	MPO TPO	1.05e-04	6	50	2	PS00435
Domain	APC_su10/DOC_dom	CUL9 HERC2	1.46e-04	7	50	2	IPR004939
Domain	DOC	CUL9 HERC2	1.46e-04	7	50	2	PS51284
Domain	APC10	CUL9 HERC2	1.46e-04	7	50	2	SM01337
Domain	ANAPC10	CUL9 HERC2	1.46e-04	7	50	2	PF03256
Domain	Haem_peroxidase	MPO TPO	3.12e-04	10	50	2	IPR010255
Domain	An_peroxidase	MPO TPO	3.12e-04	10	50	2	PF03098
Domain	PEROXIDASE_3	MPO TPO	3.12e-04	10	50	2	PS50292
Domain	Haem_peroxidase_animal	MPO TPO	3.12e-04	10	50	2	IPR019791
Domain	-	MPO TPO	3.12e-04	10	50	2	1.10.640.10
Domain	Rib_L2_dom2	CUL9 HERC2	1.05e-03	18	50	2	IPR014722
Domain	-	CUL9 HERC2	1.05e-03	18	50	2	2.30.30.30
Domain	Kringle-like	PLAU MMP9	3.31e-03	32	50	2	IPR013806
Pathway	WP_AFFECTED_PATHWAYS_IN_DUCHENNE_MUSCULAR_DYSTROPHY	MPO PLAU MMP9 SMAD4	5.54e-05	74	40	4	M48080
Pathway	KEGG_MEDICUS_VARIANT_TMPRSS2_ERG_FUSION_TO_TRANSCRIPTIONAL_ACTIVATION	PLAU MMP9	1.63e-04	7	40	2	M47443
Pubmed	Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells.	PLAU MMP9 SMAD4	6.28e-08	6	52	3	24340014
Pubmed	ω-3 Long-Chain Polyunsaturated Fatty Acids and Fatty Acid Desaturase Activity Ratios as Eventual Endophenotypes for ADHD.	MPO MMP9	2.19e-06	2	52	2	23100268
Pubmed	Postprandial serum induces apoptosis in endothelial cells: Role of polymorphonuclear-derived myeloperoxidase and metalloproteinase-9 activity.	MPO MMP9	2.19e-06	2	52	2	18177875
Pubmed	Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion.	PLAU MMP9	2.19e-06	2	52	2	18355442
Pubmed	Isolation of a complementary DNA clone for thyroid microsomal antigen. Homology with the gene for thyroid peroxidase.	MPO TPO	2.19e-06	2	52	2	3654979
Pubmed	Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9.	PLAU MMP9	2.19e-06	2	52	2	21075828
Pubmed	Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression.	PLAU MMP9	2.19e-06	2	52	2	9079647
Pubmed	Salivary and plasma levels of matrix metalloproteinase-9 and myeloperoxidase at rest and after acute physical exercise in patients with coronary artery disease.	MPO MMP9	2.19e-06	2	52	2	30726210
Pubmed	The influence of opioid peptides on matrix metalloproteinase-9 and urokinase plasminogen activator expression in three cancer cell lines.	PLAU MMP9	2.19e-06	2	52	2	23350235
Pubmed	Cerebrospinal fluid u-plasminogen activator and matrix metalloproteinase-9 levels in human eosinophilic meningitis associated with angiostrongyliasis.	PLAU MMP9	2.19e-06	2	52	2	20584616
Pubmed	Low plasma levels of HSP70 in patients with carotid atherosclerosis are associated with increased levels of proteolytic markers of neutrophil activation.	MPO MMP9	2.19e-06	2	52	2	17161406
Pubmed	Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis.	PLAU MMP9	2.19e-06	2	52	2	16880329
Pubmed	High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases.	MPO MMP9	2.19e-06	2	52	2	33027796
Pubmed	Effect of DPC4 gene on invasion and metastasis of colorectal carcinoma cells.	MMP9 SMAD4	2.19e-06	2	52	2	17151782
Pubmed	Regulatory Effects of Urokinase on Mesenchymal Stromal Cell Migration, Proliferation, and Matrix Metalloproteinase Secretion.	PLAU MMP9	6.57e-06	3	52	2	27783304
Pubmed	Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.	PLAU MMP9	6.57e-06	3	52	2	19147749
Pubmed	Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.	PLAU MMP9	6.57e-06	3	52	2	28278500
Pubmed	Exposure of cryptic domains in the alpha 1-chain of laminin-1 by elastase stimulates macrophages urokinase and matrix metalloproteinase-9 expression.	PLAU MMP9	6.57e-06	3	52	2	11827968
Pubmed	De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.	PLAU MMP9	6.57e-06	3	52	2	19903858
Pubmed	Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and Its Relation to Coronary Artery Disease).	MPO MMP9	6.57e-06	3	52	2	26132583
Pubmed	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in adult human sarcoma cell lines.	PLAU MMP9	6.57e-06	3	52	2	23661254
Pubmed	Urokinase plasminogen activator is a central regulator of macrophage three-dimensional invasion, matrix degradation, and adhesion.	PLAU MMP9	6.57e-06	3	52	2	24616477
Pubmed	Implication of MMP-9 and urokinase plasminogen activator (uPA) in the activation of pro-matrix metalloproteinase (MMP)-13.	PLAU MMP9	6.57e-06	3	52	2	21913037
Pubmed	Kinin B1 receptor activation turns on exocytosis of matrix metalloprotease-9 and myeloperoxidase in human neutrophils: involvement of mitogen-activated protein kinase family.	MPO MMP9	6.57e-06	3	52	2	19641039
Pubmed	ROS-NFkappaB mediates TGF-beta1-induced expression of urokinase-type plasminogen activator, matrix metalloproteinase-9 and cell invasion.	PLAU MMP9	6.57e-06	3	52	2	20204677
Pubmed	Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases.	MPO MMP9	6.57e-06	3	52	2	20636397
Pubmed	FOXM1-mediated downregulation of uPA and MMP9 by 3,3'-diindolylmethane inhibits migration and invasion of human colorectal cancer cells.	PLAU MMP9	6.57e-06	3	52	2	25962429
Pubmed	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.	PLAU MMP9	6.57e-06	3	52	2	11025665
Pubmed	Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.	PLAU MMP9	6.57e-06	3	52	2	19723042
Pubmed	Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy.	MPO MMP9	1.31e-05	4	52	2	19995403
Pubmed	Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.	PLAU MMP9	1.31e-05	4	52	2	15631996
Pubmed	Concomitant lack of MMP9 and uPA disturbs physiological tissue remodeling.	PLAU MMP9	1.31e-05	4	52	2	21802414
Pubmed	Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways.	PLAU MMP9	1.31e-05	4	52	2	22684547
Pubmed	Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in pediatric human sarcoma cell lines.	PLAU MMP9	1.31e-05	4	52	2	23900236
Pubmed	Common genetic variants in the plasminogen activation pathway are not associated with multiple sclerosis.	PLAU MMP9	1.31e-05	4	52	2	23897640
Pubmed	Smoking and matrix metalloproteinases, neutrophil elastase and myeloperoxidase in chronic periodontitis.	MPO MMP9	1.31e-05	4	52	2	20646231
Pubmed	Inhibition of tumor growth by β-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model.	PLAU MMP9	1.31e-05	4	52	2	25405459
Pubmed	Upregulation of urokinase-type plasminogen activator and inhibitor and gelatinase expression via 3 mitogen-activated protein kinases and PI3K pathways during the early development of osteoarthritis.	PLAU MMP9	1.31e-05	4	52	2	17299841
Pubmed	Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.	PLAU MMP9	1.31e-05	4	52	2	14617754
Pubmed	The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.	TPO PLAU FGFR4 SMAD4	1.51e-05	99	52	4	19730683
Pubmed	[Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma].	PLAU MMP9	2.19e-05	5	52	2	26978018
Pubmed	Inhibition of histone deacetylase activity in human endometrial stromal cells promotes extracellular matrix remodelling and limits embryo invasion.	PLAU MMP9	2.19e-05	5	52	2	22291969
Pubmed	Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.	PLAU MMP9	2.19e-05	5	52	2	25544710
Pubmed	Macrophages of M1 phenotype have properties that influence lung cancer cell progression.	PLAU MMP9	2.19e-05	5	52	2	26050228
Pubmed	Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma.	MPO PLAU	3.28e-05	6	52	2	20651370
Pubmed	Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.	PLAU MMP9	3.28e-05	6	52	2	10502816
Pubmed	[Matrix metalloproteinases (MMP)--MMP-1,-2,-9 and its endogenous activity regulators in transformed by E7 oncogene HPV16 and HPV18 cervical carcinoma cell lines].	PLAU MMP9	3.28e-05	6	52	2	24479343
Pubmed	Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.	PLAU MMP9	3.28e-05	6	52	2	21574189
Pubmed	Synergy between a plasminogen cascade and MMP-9 in autoimmune disease.	PLAU MMP9	3.28e-05	6	52	2	15841177
Pubmed	Genetic analysis of autoimmune type 1 diabetes mellitus in mice.	MPO CHRNB1	3.28e-05	6	52	2	1675432
Pubmed	Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation.	PLAU MMP9	3.28e-05	6	52	2	9398846
Pubmed	Mapping of the nu gene using congenic nude strains and in situ hybridization.	MPO CHRNB1	3.28e-05	6	52	2	1346798
Pubmed	Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation.	PLAU MMP9	4.58e-05	7	52	2	10090151
Pubmed	Alzheimer Disease Overview	MPO PLAU	4.58e-05	7	52	2	20301340
Pubmed	Regional localization of the nu mutation on mouse chromosome 11.	MPO CHRNB1	4.58e-05	7	52	2	8423056
Pubmed	Human chromosome 17 comparative anchor loci are conserved on bovine chromosome 19.	MPO CHRNB1	6.10e-05	8	52	2	7557995
Pubmed	Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice.	PLAU MMP9	7.84e-05	9	52	2	16224065
Pubmed	Impact of donor-dependent genetic factors on long-term renal graft function.	MPO MMP9	7.84e-05	9	52	2	19857655
Pubmed	Additional microsatellite markers for mouse genome mapping.	MPO PLAU CHRNB1	1.17e-04	63	52	3	1794058
Pubmed	Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor.	PLAU MMP9	1.20e-04	11	52	2	7743917
Pubmed	Characterization of novel secreted and membrane proteins isolated by the signal sequence trap method.	FRRS1 RPN1	1.20e-04	11	52	2	8938438
Pubmed	The NuRD chromatin-remodeling enzyme CHD4 promotes embryonic vascular integrity by transcriptionally regulating extracellular matrix proteolysis.	PLAU MMP9	1.20e-04	11	52	2	24348274
Pubmed	JunB is essential for mammalian placentation.	PLAU MMP9	2.27e-04	15	52	2	10022836
Pubmed	A candidate gene approach to genetic prognostic factors of IgA nephropathy--a result of Polymorphism REsearch to DIstinguish genetic factors Contributing To progression of IgA Nephropathy (PREDICT-IgAN).	MPO TPO MMP9	2.39e-04	80	52	3	19420105
Pubmed	A TGFβ-Smad4-Fgf6 signaling cascade controls myogenic differentiation and myoblast fusion during tongue development.	FGFR4 SMAD4	2.60e-04	16	52	2	22438570
Pubmed	Derivation and characterization of a somatic cell hybrid containing the portion of mouse chromosome 11 (MMU11) homologous to human chromosome 17q.	MPO CHRNB1	2.60e-04	16	52	2	8683100
Pubmed	High-throughput analysis of promoter occupancy reveals new targets for Arx, a gene mutated in mental retardation and interneuronopathies.	RPN1 NXF1	2.94e-04	17	52	2	21966449
Pubmed	SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis.	PLAU MMP9	2.94e-04	17	52	2	18667463
Pubmed	Regulation of developmental lymphangiogenesis by Syk(+) leukocytes.	MPO MMP9	3.30e-04	18	52	2	20230750
Pubmed	Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma.	MPO ATG9B	3.30e-04	18	52	2	19423521
Pubmed	A high-resolution map of the chromosomal region surrounding the nude gene.	MPO CHRNB1	3.69e-04	19	52	2	7601457
Pubmed	Targeting Interleukin-1β Reduces Leukocyte Production After Acute Myocardial Infarction.	MPO MMP9	4.09e-04	20	52	2	26358260
Pubmed	Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.	RPN1 SAFB2 NXF1	5.16e-04	104	52	3	26167872
Pubmed	Bone morphogenetic protein receptor 1A signaling is dispensable for hematopoietic development but essential for vessel and atrioventricular endocardial cushion formation.	PLAU SMAD4	6.43e-04	25	52	2	16887829
Pubmed	The ubiquitin-specific protease USP36 SUMOylates EXOSC10 and promotes the nucleolar RNA exosome function in rRNA processing.	MPO RPN1 MRPS18B MMP9 NXF1	7.68e-04	483	52	5	36912080
Pubmed	Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development.	MPO RPN1 MRPS18B CUL9 MMP9	8.65e-04	496	52	5	31343991
Pubmed	Identification and characterization of SAP25, a novel component of the mSin3 corepressor complex.	TTLL12 DDX3Y	9.29e-04	30	52	2	16449650
Pubmed	Human neutrophils secrete bioactive paucimannosidic proteins from azurophilic granules into pathogen-infected sputum.	MPO MMP9	9.92e-04	31	52	2	25645918
Pubmed	Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBPalpha.	MPO MMP9	1.06e-03	32	52	2	9611252
Pubmed	LKB1 deletion causes early changes in atrial channel expression and electrophysiology prior to atrial fibrillation.	MMP9 RYR2	1.19e-03	34	52	2	26378152
Pubmed	Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria.	MPO TPO LDHD POLG PCK2	1.28e-03	542	52	5	14651853
Pubmed	Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population.	LRFN2 KCNK15 CUL9 MYO15A ARHGAP11A RYR2	1.31e-03	814	52	6	23251661
Cytoband	3q25.1	AADAC TSC22D2	6.50e-04	33	52	2	3q25.1
Cytoband	10q22.2	DNAJC9-AS1 PLAU	1.00e-03	41	52	2	10q22.2
GeneFamily	Endogenous ligands\|Minor histocompatibility antigens	TRIM42 DDX3Y	3.67e-03	51	32	2	870
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell-Podocyte\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PPP1R15A ALS2CL CHRNB1 KCNH3	3.56e-05	159	52	4	fd7db2f7328cfefdc3ada2af91006d5a91d137e1
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PPP1R15A ALS2CL CHRNB1 KCNH3	3.56e-05	159	52	4	aaf449c768d6fbb0a1bb47746ff3bdb7f9eb8914
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-glomerular_visceral_epithelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PPP1R15A ALS2CL CHRNB1 KCNH3	3.56e-05	159	52	4	8bbdef1e927f3130b578d7d7c5ff38bbe06fab63
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MPO ATG9B PLAU RYR2	4.12e-05	165	52	4	6d315e0734079ad05336cc2c3f24d870c9105bc8
ToppCell	facs-Marrow-B-cells-24m-Myeloid-granulocyte_monocyte_progenitor_cell\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MPO ATG9B PLAU RYR2	4.12e-05	165	52	4	84f5597b1bb75f42de9a224196bb8ac198bbe3bf
ToppCell	368C-Fibroblasts-Fibroblast-C_(Myofibroblast)-\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	FMO5 FGFR4 PCK2 RYR2	4.42e-05	168	52	4	c66a61d3ec711796313a2c6d2dc39aedbfc20afd
ToppCell	368C-Fibroblasts-Fibroblast-C_(Myofibroblast)\|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells)	FMO5 FGFR4 PCK2 RYR2	4.42e-05	168	52	4	83b4f817d95daa15ae60668e789f97d8a3b2e6dd
ToppCell	severe_COVID-19-Neutrophil\|World / disease group, cell group and cell class (v2)	PLAU FGFR4 PPP1R15A MMP9	4.62e-05	170	52	4	dfc807e0dd66179490a258ecbe8eb439e715799d
ToppCell	severe_COVID-19-Neutrophil\|severe_COVID-19 / disease group, cell group and cell class (v2)	PLAU FGFR4 PPP1R15A MMP9	4.84e-05	172	52	4	8f4bcb9b2bbf8b4333f673d8ad6bb88dfda4792a
ToppCell	droplet-Spleen-SPLEEN-30m\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MPO RSRP1 DDX3Y MMP9	4.84e-05	172	52	4	02cc4a9fb7902c572cee37ba828749db4913ee87
ToppCell	IIH-Treg-proli_CD4\|IIH / Condition, Cell_class and T cell subcluster	JMJD8 MYO15A PCK2 NXF1	6.03e-05	182	52	4	5c7d02da9ca2bca49db9832704b6894dfaa08a71
ToppCell	facs-Trachea-24m-Epithelial-glandular_epithelial\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TPO LLGL2 CHRNB1 KCNH3	6.29e-05	184	52	4	61caaa31975e05c9a6512079c791fed5a9e2d39f
ToppCell	facs-Trachea-24m-Epithelial-glandular_epithelial-lung_secretory_cell\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TPO LLGL2 CHRNB1 KCNH3	6.29e-05	184	52	4	03da0f0f89f1ca5a3ccca1e22972f3129464e68e
ToppCell	facs-Trachea-24m-Epithelial-glandular_epithelial-lung_secretory_cell-mucous\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TPO LLGL2 CHRNB1 KCNH3	6.29e-05	184	52	4	9ed2a65a4ca0ebbbb89ace61027522f93369843d
ToppCell	PND10-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-AEC-AEC_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TTLL12 LLGL2 FMO5 IMPACT	6.42e-05	185	52	4	87151ab95530e70d61328b336518df58db584acb
ToppCell	facs-Trachea-nan-24m-Epithelial-mucus_secreting_cell\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TPO LLGL2 CHRNB1 KCNH3	6.42e-05	185	52	4	e502ec54971f518d0cf1b619b745607a8ab5ddf3
ToppCell	facs-Limb_Muscle\|facs / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PLAU FGFR4 PPP1R15A CHRNB1	6.98e-05	189	52	4	21ec43859d21ffc565acbe36489da1d2d0f9877d
ToppCell	facs-Marrow-KLS-3m-Myeloid\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MPO ATG9B LMF1 RPN1	6.98e-05	189	52	4	b28a0e2d5a5f512f9b137b162b195bdc3d5ee9ba
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-Z\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	DDX3Y PLAU TSC22D2 PPP1R15A	7.12e-05	190	52	4	4d401b73c0e7eb38e95d0851a128bf12bb0d3a9f
ToppCell	facs-Thymus-Flowthrough-3m\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MIDN RSRP1 ALS2CL KCNH3	7.41e-05	192	52	4	7a0ef1702d6538e5611cfdc633d8558f9523845c
ToppCell	facs-Thymus-Flowthrough-3m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MIDN RSRP1 ALS2CL KCNH3	7.41e-05	192	52	4	05043fb75319b64f5ed7aee6a232309dcae891b8
ToppCell	Control-B_naive-13\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	MIDN RSRP1 DDX3Y PPP1R15A	7.56e-05	193	52	4	32e53a6473a682cf14b20a399c3686f658298b93
ToppCell	TCGA-Head_and_Esophagus-Primary_Tumor\|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9	RPN1 PLAU MMP9 ARHGAP11A	8.19e-05	197	52	4	1bb8f9535a9ab6c7a444bcbe346fcc0a13b09bdf
ToppCell	distal-2\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	MIDN DDX3Y PPP1R15A FCN3	8.68e-05	200	52	4	7a355c3883fd409b2e0868164bb6e7ce4b745776
ToppCell	mLN-Dendritic_cell-cDC2\|Dendritic_cell / Region, Cell class and subclass	MIDN R3HCC1 PLAU MMP9	8.68e-05	200	52	4	e3f7852aaa26a9b3e626d85e40afde799e873045
Computational	Fetal liver genes - metabolism and xenobiotics.	MPO TTLL12 AADAC LLGL2 FGFR4 PPP1R15A PCK2 CHRNB1	9.98e-05	453	36	8	MODULE_24
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; MCF7; HT_HG-U133A	PACS1 FMO5 PPP1R15A MMP9 ALS2CL RYR2	4.78e-06	195	51	6	6845_DN
Drug	Hydrastinine hydrochloride [4884-68-8]; Down 200; 16.4uM; MCF7; HT_HG-U133A	FMO5 POLG PLAU FGFR4 TSC22D2 RYR2	4.78e-06	195	51	6	2283_DN
Drug	xylosides	PLAU MMP9	4.92e-06	2	51	2	ctd:C010807
Drug	salicylhydroxamic acid	MPO TPO	4.92e-06	2	51	2	ctd:C005703
Drug	SB 3CT compound	PLAU MMP9	1.47e-05	3	51	2	ctd:C429533
Drug	alpha-benzoylamino-1,4-naphthoquinone	PLAU MMP9	1.47e-05	3	51	2	ctd:C109682
Drug	fucoidan	MPO FGFR4 MMP9	2.65e-05	26	51	3	ctd:C007789
Disease	chronic obstructive pulmonary disease (biomarker_via_orthology)	MPO MMP9 SMAD4	1.29e-05	28	48	3	DOID:3083 (biomarker_via_orthology)
Disease	Alzheimer disease type 1	MPO PLAU	1.55e-05	4	48	2	cv:C1863052
Disease	ALZHEIMER DISEASE, FAMILIAL, 1	MPO PLAU	1.55e-05	4	48	2	104300
Disease	Alzheimer's disease 1 (is_implicated_in)	MPO PLAU	1.55e-05	4	48	2	DOID:0080348 (is_implicated_in)
Disease	Early-onset autosomal dominant Alzheimer disease	MPO PLAU	5.41e-05	7	48	2	cv:CN043596
Disease	Vasogenic Brain Edema	PLAU MMP9	7.21e-05	8	48	2	C0750969
Disease	Bone neoplasms	PLAU MMP9	7.21e-05	8	48	2	C0005967
Disease	Cytotoxic Brain Edema	PLAU MMP9	7.21e-05	8	48	2	C0750970
Disease	Alzheimer disease	MPO PLAU	7.21e-05	8	48	2	cv:C0002395
Disease	Malignant Bone Neoplasm	PLAU MMP9	7.21e-05	8	48	2	C0279530
Disease	Cytotoxic Cerebral Edema	PLAU MMP9	7.21e-05	8	48	2	C0472388
Disease	Vasogenic Cerebral Edema	PLAU MMP9	7.21e-05	8	48	2	C0472387
Disease	Brain Edema	PLAU MMP9	7.21e-05	8	48	2	C1527311
Disease	Cerebral Edema	PLAU MMP9	7.21e-05	8	48	2	C0006114
Disease	bacterial pneumonia (is_marker_for)	MPO MMP9	9.26e-05	9	48	2	DOID:874 (is_marker_for)
Disease	Brain Ischemia	MPO PLAU MMP9	1.30e-04	60	48	3	C0007786
Disease	Cerebral Ischemia	MPO PLAU MMP9	1.30e-04	60	48	3	C0917798
Disease	Ulcerative Colitis	MPO HERC2 MMP9	1.50e-04	63	48	3	C0009324
Disease	pulmonary fibrosis (implicated_via_orthology)	PLAU SMAD4	1.69e-04	12	48	2	DOID:3770 (implicated_via_orthology)
Disease	salicylurate measurement	LMF1 RYR2	2.00e-04	13	48	2	EFO_0010532
Disease	brain edema (biomarker_via_orthology)	PLAU MMP9	2.68e-04	15	48	2	DOID:4724 (biomarker_via_orthology)
Disease	pulmonary hypertension (biomarker_via_orthology)	MMP9 RYR2 SMAD4	3.04e-04	80	48	3	DOID:6432 (biomarker_via_orthology)
Disease	sinusitis (is_marker_for)	PLAU MMP9	3.90e-04	18	48	2	DOID:0050127 (is_marker_for)
Disease	Reperfusion Injury	MPO PLAU MMP9	4.16e-04	89	48	3	C0035126
Disease	squamous cell carcinoma (is_marker_for)	PLAU MMP9	4.35e-04	19	48	2	DOID:1749 (is_marker_for)
Disease	chronic obstructive pulmonary disease (is_marker_for)	MPO PLAU MMP9	5.35e-04	97	48	3	DOID:3083 (is_marker_for)
Disease	status epilepticus (biomarker_via_orthology)	POLG PLAU MMP9	5.85e-04	100	48	3	DOID:1824 (biomarker_via_orthology)
Disease	Pancreatic Neoplasm	PLAU MMP9 SMAD4	5.85e-04	100	48	3	C0030297
Disease	Malignant neoplasm of pancreas	PLAU MMP9 SMAD4	6.20e-04	102	48	3	C0346647
Disease	urinary bladder cancer (is_marker_for)	PLAU MMP9 SMAD4	7.12e-04	107	48	3	DOID:11054 (is_marker_for)
Disease	interstitial lung disease (is_marker_for)	MPO MMP9	7.59e-04	25	48	2	DOID:3082 (is_marker_for)
Disease	myeloperoxidase measurement	MPO RPN1	8.21e-04	26	48	2	EFO_0005243
Disease	Cerebral Hemorrhage	PLAU MMP9	9.53e-04	28	48	2	C2937358
Disease	Bipolar Disorder	TPO PACS1 POLG IMPACT MMP9	1.04e-03	477	48	5	C0005586
Disease	asthma (is_marker_for)	MPO PLAU MMP9	1.14e-03	126	48	3	DOID:2841 (is_marker_for)
Disease	renal cell carcinoma (is_marker_for)	PLAU MMP9 SMAD4	1.20e-03	128	48	3	DOID:4450 (is_marker_for)
Disease	Cholestasis, Extrahepatic	MPO MMP9	1.25e-03	32	48	2	C0005398
Disease	Anoxemia	MPO PCK2	1.32e-03	33	48	2	C0003129
Disease	Hypoxemia	MPO PCK2	1.32e-03	33	48	2	C0700292
Disease	Hypoxia	MPO PCK2	1.32e-03	33	48	2	C0242184
Disease	Anoxia	MPO PCK2	1.32e-03	33	48	2	C0003130
Disease	sleep measurement	TPO ARHGAP11A RYR2	1.39e-03	135	48	3	EFO_0004870
Disease	Middle Cerebral Artery Embolus	PLAU MMP9	1.41e-03	34	48	2	C0751845
Disease	Embolic Infarction, Middle Cerebral Artery	PLAU MMP9	1.41e-03	34	48	2	C0751847
Disease	Left Middle Cerebral Artery Infarction	PLAU MMP9	1.41e-03	34	48	2	C0751846
Disease	Right Middle Cerebral Artery Infarction	PLAU MMP9	1.41e-03	34	48	2	C0751849
Disease	Thrombotic Infarction, Middle Cerebral Artery	PLAU MMP9	1.41e-03	34	48	2	C0751848
Disease	Middle Cerebral Artery Occlusion	PLAU MMP9	1.41e-03	34	48	2	C0740391
Disease	Infarction, Middle Cerebral Artery	PLAU MMP9	1.41e-03	34	48	2	C0740392
Disease	Middle Cerebral Artery Thrombosis	PLAU MMP9	1.41e-03	34	48	2	C0740376
Disease	Middle Cerebral Artery Syndrome	PLAU MMP9	1.41e-03	34	48	2	C0238281
Disease	endometrial carcinoma (is_marker_for)	MMP9 SMAD4	1.41e-03	34	48	2	DOID:2871 (is_marker_for)
Disease	Liver Cirrhosis, Experimental	AADAC RSRP1 PLAU MMP9 PCK2 SMAD4	1.53e-03	774	48	6	C0023893

Protein segments in the cluster

Peptide	Gene	Start	Entry
ATYEGEWCRGRPHGK	ALS2CL	356	Q60I27
PFRYTGHWERGQRSG	ALS2CL	456	Q60I27
RAGSLRYHGPDWRIF	ANTXRL	26	A6NF34
EALRRGLFYIHGGGW	AADAC	101	P22760
ERGGHWYKEGSRLAP	FGFR4	61	P22455
SGWGRGTDEYFIRKP	CHRNB1	381	P11230
LRPGDYRRYHDWGGA	CRYGA	146	P11844
GRPGFGGRRRFFWKT	CDR1	216	P51861
RRYGVSHPDAGAAWR	NAGLU	481	P54802
GARAGRWYRGRKPDQ	R3HCC1	121	Q9Y3T6
GPDRWKETGGGRRRY	KCNH3	141	Q9ULD8
WASGRGVGHPYRRVR	FCN3	281	O75636
DGKYWRFSEGRGSRP	MMP9	536	P14780
DPWAGYRYTGKLRPH	METAP1	76	P53582
YRWKGHERLAARSGP	LLGL2	556	Q6P1M3
WRFGTIHGRVGRFPS	MYO15A	2931	Q9UKN7
DLYTWGKGRYGRLGH	HERC2	4111	O95714
PHRAGRQWKFPGSFY	KCNK15	71	Q9H427
RVYRGGKWPHGAVGV	LMLN	186	Q96KR4
RRDEAGHFLWPGFGE	PCK2	536	Q16822
RGPFRWKYGEGNRRS	NXF1	26	Q9UBU9
SRDHGLPGYNAWRRF	MPO	591	P05164
QRGRDHGLPGYNEWR	TPO	581	P07202
ERHGWGYLVPGRRDN	POLG	616	P54098
RWYGGILLGPDRFKH	IMPACT	266	Q9P2X3
YWLGHPGERRREGDK	PACS1	826	Q6VY07
RGGWSRHAGYHPYLG	FRRS1	436	Q6ZNA5
IHYRVQGPGKWDGAR	FMO5	471	P49326
HTAGRGRHFRFGFWP	LDHD	201	Q86WU2
LFRGGWELPHAYKRS	ATG9B	411	Q674R7
KHEWRPLFAREGGIY	CUL9	761	Q8IWT3
GLVAWVHGDPRRAAY	SLC44A5	56	Q8NCS7
GAWPRRASALYGGRK	DNAJC9-AS1	41	A6NH13
RPGFGRFERSGHSRW	DDX3Y	111	O15523
WGQPFRLRHVTTGKY	RYR2	291	Q92736
RAHFRGWGYRPGKET	PPP1R15A	476	O75807
DARGPYHWSPSRKAG	MIDN	411	Q504T8
RGRAWYKGSPKHPIG	ARHGAP11A	996	Q6P4F7
EHGYLKWRFDRSSGP	TRIM42	221	Q8IWZ5
PWFAAIYRRHRGGSV	PLAU	191	P00749
KLDHGSGEPYRRGRW	TSC22D2	166	O75157
HGYHGWGCRRERGPQ	PELI3	366	Q8N2H9
GRKGFPHVIYARLWR	SMAD4	86	Q13485
IRPRFPLFGGWKTHY	RPN1	316	P04843
GFGRTVYPEEHSRWR	RSRP1	141	Q9BUV0
RPVWADYRRNHKGGV	MRPS18B	71	Q9Y676
IEGRKEHYRRWEPGS	TTC14	651	Q96N46
PERHGRDSRDGWGGY	SAFB2	811	Q14151
ASGVPERYWGRLLHK	TTLL12	41	Q14166
IKRVEGRSWYTPHRG	TRIP4	451	Q15650
HGPGYSEVIYGRKRW	JMJD8	181	Q96S16
WVRGEHYRYKFSRPG	LMF1	511	Q96S06
GSPGGLKGRYFWHVR	LRFN2	266	Q9ULH4